- Home
- CRDL vs DLHC Comparison
CRDL vs DLHC Comparison
Compare CRDL & DLHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- DLHC
- Stock Information
- Founded
- CRDL 2017
- DLHC 1969
- Country
- CRDL Canada
- DLHC United States
- Employees
- CRDL N/A
- DLHC N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- DLHC Business Services
- Sector
- CRDL Health Care
- DLHC Consumer Discretionary
- Exchange
- CRDL Nasdaq
- DLHC Nasdaq
- Market Cap
- CRDL 125.7M
- DLHC 117.4M
- IPO Year
- CRDL N/A
- DLHC N/A
- Fundamental
- Price
- CRDL $1.28
- DLHC $7.67
- Analyst Decision
- CRDL Strong Buy
- DLHC
- Analyst Count
- CRDL 3
- DLHC 0
- Target Price
- CRDL $9.00
- DLHC N/A
- AVG Volume (30 Days)
- CRDL 391.0K
- DLHC 54.5K
- Earning Date
- CRDL 11-14-2024
- DLHC 01-29-2025
- Dividend Yield
- CRDL N/A
- DLHC N/A
- EPS Growth
- CRDL N/A
- DLHC 410.00
- EPS
- CRDL N/A
- DLHC 0.51
- Revenue
- CRDL N/A
- DLHC $395,937,000.00
- Revenue This Year
- CRDL N/A
- DLHC N/A
- Revenue Next Year
- CRDL N/A
- DLHC N/A
- P/E Ratio
- CRDL N/A
- DLHC $15.04
- Revenue Growth
- CRDL N/A
- DLHC 5.34
- 52 Week Low
- CRDL $0.79
- DLHC $7.34
- 52 Week High
- CRDL $3.12
- DLHC $17.58
- Technical
- Relative Strength Index (RSI)
- CRDL 26.78
- DLHC 40.87
- Support Level
- CRDL $1.27
- DLHC $7.34
- Resistance Level
- CRDL $1.46
- DLHC $8.14
- Average True Range (ATR)
- CRDL 0.10
- DLHC 0.41
- MACD
- CRDL -0.00
- DLHC -0.03
- Stochastic Oscillator
- CRDL 3.33
- DLHC 15.49
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About DLHC DLH Holdings Corp.
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. It is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, and telehealth systems.